A different method for obtaining an engineered murine antibody, that recognizes epidermal growth factor receptor, with reduced immunogenicity

Biotecnologia Aplicada 1997 Volume 14 No. 1, pp.58 A different method for obtaining an engineered murine antibody, that recognizes epidermal growth factor receptor, with reduced immunogenicity Cristina Mateo, Josefa Lombardero, Ernesto Moreno, Gumersinda Bombino and Rolando Perez Code Number:BA970019 Size of Files: Text: 5.6K Graphics: No associated graphics files Introduction Monoclonal antibody producing hybridomas have been most readily obtained from immunized rodents. In most cases where rodent antibodies have been used for therapy, the recipients have elicited an immune response directed towards the antibody. These reactions have limited the duration and effectiveness of the therapy. The engineered antibodies have been designed to replace as much as possible the xenogeneic sequences with the equivalent human sequences. Chimeric and humanized antibodies are among the genetically-engineered antibodies. It is worth noting that even the replacement of the constant regions with human equivalents may not abolish their immunogenicity, still approximately half of the recipients mounts an immune response to the rodent variable regions. Copyright 1997 Elfos Scientia